Related Experiment Video

Updated: Dec 18, 2025

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.6K

Potential drug interactions between targeted oral antineoplastic agents and concomitant medication in clinical

Vicente Escudero-Vilaplana1, Roberto Collado-Borrell1, Angela Hoyo-Muñoz1

  • 1Pharmacy Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón , Madrid, Spain.

Expert Opinion on Drug Safety
|June 13, 2020
PubMed
Abstract

Insights

Over half of cancer patients on targeted oral anticancer agents (OAAs) experienced potential drug interactions (PDIs). Key risk factors for PDIs include polypharmacy and specific cancer types like prostate cancer.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Pharmacy

Background:

  • Targeted oral anticancer agents (OAAs) are increasingly used in cancer care.
  • Concomitant medications are common in cancer patients, increasing the risk of drug interactions.
  • Understanding potential drug interactions (PDIs) is crucial for patient safety.

Purpose of the Study:

  • To analyze the incidence and risk factors of PDIs between targeted OAAs and concomitant therapies in cancer outpatients.
  • To identify patient populations at higher risk for experiencing PDIs.

Main Methods:

  • A cross-sectional observational study of 881 cancer outpatients initiating targeted OAAs.
  • PDIs were assessed using Lexicomp® and About Herbs® databases.
  • Risk factors for PDIs were identified through univariate and multivariate analyses.

Main Results:

  • 50.9% of patients experienced at least one PDI.
  • Polypharmacy (≥5 medications) significantly increased PDI risk (OR=3.64).
  • Specific cancer types (prostate cancer, chronic myelogenous leukemia, sarcoma) and hormone therapies were associated with higher PDI risk.

Conclusions:

  • PDIs are common in patients receiving targeted OAAs.
  • Prioritizing PDI screening is essential, particularly for patients with identified risk factors.
  • Risk factors include polypharmacy, prostate cancer, chronic myelogenous leukemia, sarcoma, and hormone therapy use.
Keywords:
Cancer outpatientsdrug interactionsoral antineoplastic agentssafety

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.5K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.3K

Related Concept Videos

Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
254
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.3K
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
145
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
513
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
6.6K